nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—PPARG—colon cancer	0.608	1	CbGaD
Repaglinide—SLCO1B1—Irinotecan—colon cancer	0.0873	0.276	CbGbCtD
Repaglinide—ALB—Irinotecan—colon cancer	0.0478	0.151	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—colon cancer	0.0462	0.146	CbGbCtD
Repaglinide—ALB—Fluorouracil—colon cancer	0.0459	0.145	CbGbCtD
Repaglinide—CYP2C8—Fluorouracil—colon cancer	0.0355	0.112	CbGbCtD
Repaglinide—ALB—Methotrexate—colon cancer	0.0253	0.0801	CbGbCtD
Repaglinide—CYP3A4—Irinotecan—colon cancer	0.015	0.0474	CbGbCtD
Repaglinide—CYP3A4—Vincristine—colon cancer	0.0131	0.0414	CbGbCtD
Repaglinide—PPARG—Topotecan—Irinotecan—colon cancer	0.00374	1	CbGdCrCtD
Repaglinide—Ischaemia—Irinotecan—colon cancer	0.00235	0.0472	CcSEcCtD
Repaglinide—PPARG—endothelium—colon cancer	0.00207	0.0917	CbGeAlD
Repaglinide—PPARG—blood vessel—colon cancer	0.00191	0.0846	CbGeAlD
Repaglinide—ALB—gall bladder—colon cancer	0.00169	0.0746	CbGeAlD
Repaglinide—ABCC8—smooth muscle tissue—colon cancer	0.00117	0.052	CbGeAlD
Repaglinide—PPARG—embryo—colon cancer	0.00114	0.0504	CbGeAlD
Repaglinide—ABCC8—renal system—colon cancer	0.00113	0.05	CbGeAlD
Repaglinide—Myocardial ischaemia—Irinotecan—colon cancer	0.00107	0.0214	CcSEcCtD
Repaglinide—Myocardial ischaemia—Fluorouracil—colon cancer	0.00102	0.0205	CcSEcCtD
Repaglinide—KCNJ11—lymphoid tissue—colon cancer	0.00102	0.0451	CbGeAlD
Repaglinide—SLCO1B1—renal system—colon cancer	0.001	0.0443	CbGeAlD
Repaglinide—PPARG—epithelium—colon cancer	0.00093	0.0412	CbGeAlD
Repaglinide—PPARG—smooth muscle tissue—colon cancer	0.000896	0.0397	CbGeAlD
Repaglinide—PPARG—renal system—colon cancer	0.000863	0.0382	CbGeAlD
Repaglinide—SLCO1B1—digestive system—colon cancer	0.000821	0.0363	CbGeAlD
Repaglinide—PPARG—lymphoid tissue—colon cancer	0.000716	0.0317	CbGeAlD
Repaglinide—Myocardial ischaemia—Capecitabine—colon cancer	0.000713	0.0143	CcSEcCtD
Repaglinide—PPARG—digestive system—colon cancer	0.000708	0.0313	CbGeAlD
Repaglinide—Visual disturbance—Irinotecan—colon cancer	0.000656	0.0132	CcSEcCtD
Repaglinide—PPARG—bone marrow—colon cancer	0.000652	0.0289	CbGeAlD
Repaglinide—Anaphylactoid reaction—Irinotecan—colon cancer	0.000643	0.0129	CcSEcCtD
Repaglinide—PPARG—vagina—colon cancer	0.000625	0.0277	CbGeAlD
Repaglinide—SLCO1B1—liver—colon cancer	0.000611	0.027	CbGeAlD
Repaglinide—KCNJ11—lymph node—colon cancer	0.000575	0.0254	CbGeAlD
Repaglinide—CYP2C8—renal system—colon cancer	0.000569	0.0252	CbGeAlD
Repaglinide—PPARG—liver—colon cancer	0.000527	0.0233	CbGeAlD
Repaglinide—Pancreatitis—Irinotecan—colon cancer	0.000527	0.0106	CcSEcCtD
Repaglinide—Angina pectoris—Irinotecan—colon cancer	0.000524	0.0105	CcSEcCtD
Repaglinide—Angina pectoris—Fluorouracil—colon cancer	0.000502	0.0101	CcSEcCtD
Repaglinide—ALB—liver—colon cancer	0.000495	0.0219	CbGeAlD
Repaglinide—Acute coronary syndrome—Vincristine—colon cancer	0.000485	0.00975	CcSEcCtD
Repaglinide—Myocardial infarction—Vincristine—colon cancer	0.000482	0.0097	CcSEcCtD
Repaglinide—Hepatic function abnormal—Capecitabine—colon cancer	0.000476	0.00957	CcSEcCtD
Repaglinide—Acute coronary syndrome—Irinotecan—colon cancer	0.000473	0.0095	CcSEcCtD
Repaglinide—Myocardial infarction—Irinotecan—colon cancer	0.00047	0.00944	CcSEcCtD
Repaglinide—Jaundice—Irinotecan—colon cancer	0.000467	0.00939	CcSEcCtD
Repaglinide—Haemolytic anaemia—Capecitabine—colon cancer	0.000461	0.00927	CcSEcCtD
Repaglinide—Acute coronary syndrome—Fluorouracil—colon cancer	0.000453	0.0091	CcSEcCtD
Repaglinide—Hepatic enzyme increased—Methotrexate—colon cancer	0.000451	0.00907	CcSEcCtD
Repaglinide—Myocardial infarction—Fluorouracil—colon cancer	0.00045	0.00904	CcSEcCtD
Repaglinide—Urinary tract infection—Fluorouracil—colon cancer	0.000446	0.00897	CcSEcCtD
Repaglinide—Vasculitis—Methotrexate—colon cancer	0.000437	0.00879	CcSEcCtD
Repaglinide—Rhinitis—Irinotecan—colon cancer	0.000431	0.00867	CcSEcCtD
Repaglinide—Sinusitis—Fluorouracil—colon cancer	0.000431	0.00866	CcSEcCtD
Repaglinide—Visual impairment—Irinotecan—colon cancer	0.000415	0.00833	CcSEcCtD
Repaglinide—Rhinitis—Fluorouracil—colon cancer	0.000413	0.0083	CcSEcCtD
Repaglinide—CYP2C8—vagina—colon cancer	0.000412	0.0182	CbGeAlD
Repaglinide—Cardiac disorder—Vincristine—colon cancer	0.00041	0.00824	CcSEcCtD
Repaglinide—PPARG—lymph node—colon cancer	0.000404	0.0179	CbGeAlD
Repaglinide—Cardiac disorder—Irinotecan—colon cancer	0.000399	0.00803	CcSEcCtD
Repaglinide—Alopecia—Vincristine—colon cancer	0.00039	0.00785	CcSEcCtD
Repaglinide—Immune system disorder—Irinotecan—colon cancer	0.000389	0.00781	CcSEcCtD
Repaglinide—CYP3A4—renal system—colon cancer	0.000385	0.017	CbGeAlD
Repaglinide—Arrhythmia—Irinotecan—colon cancer	0.000384	0.00773	CcSEcCtD
Repaglinide—Alopecia—Irinotecan—colon cancer	0.00038	0.00764	CcSEcCtD
Repaglinide—ALB—lymph node—colon cancer	0.000379	0.0168	CbGeAlD
Repaglinide—Back pain—Vincristine—colon cancer	0.000372	0.00748	CcSEcCtD
Repaglinide—Arrhythmia—Fluorouracil—colon cancer	0.000368	0.0074	CcSEcCtD
Repaglinide—Alopecia—Fluorouracil—colon cancer	0.000364	0.00732	CcSEcCtD
Repaglinide—Back pain—Irinotecan—colon cancer	0.000362	0.00728	CcSEcCtD
Repaglinide—Erythema—Fluorouracil—colon cancer	0.000359	0.00721	CcSEcCtD
Repaglinide—Angina pectoris—Capecitabine—colon cancer	0.000351	0.00704	CcSEcCtD
Repaglinide—CYP2C8—liver—colon cancer	0.000348	0.0154	CbGeAlD
Repaglinide—Bronchitis—Capecitabine—colon cancer	0.000346	0.00695	CcSEcCtD
Repaglinide—Leukopenia—Vincristine—colon cancer	0.000344	0.00692	CcSEcCtD
Repaglinide—Leukopenia—Irinotecan—colon cancer	0.000335	0.00674	CcSEcCtD
Repaglinide—Hypertension—Vincristine—colon cancer	0.000332	0.00667	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—colon cancer	0.000327	0.00657	CcSEcCtD
Repaglinide—Hyperglycaemia—Capecitabine—colon cancer	0.000325	0.00652	CcSEcCtD
Repaglinide—Hypertension—Irinotecan—colon cancer	0.000323	0.0065	CcSEcCtD
Repaglinide—Leukopenia—Fluorouracil—colon cancer	0.000321	0.00645	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—colon cancer	0.00032	0.00644	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000318	0.00639	CcSEcCtD
Repaglinide—Acute coronary syndrome—Capecitabine—colon cancer	0.000316	0.00636	CcSEcCtD
Repaglinide—CYP3A4—digestive system—colon cancer	0.000316	0.014	CbGeAlD
Repaglinide—Myocardial infarction—Capecitabine—colon cancer	0.000314	0.00632	CcSEcCtD
Repaglinide—Anaphylactic shock—Vincristine—colon cancer	0.000314	0.00631	CcSEcCtD
Repaglinide—Oedema—Vincristine—colon cancer	0.000314	0.00631	CcSEcCtD
Repaglinide—Jaundice—Capecitabine—colon cancer	0.000313	0.00629	CcSEcCtD
Repaglinide—Urinary tract infection—Capecitabine—colon cancer	0.000312	0.00627	CcSEcCtD
Repaglinide—Thrombocytopenia—Vincristine—colon cancer	0.000307	0.00618	CcSEcCtD
Repaglinide—Oedema—Irinotecan—colon cancer	0.000306	0.00614	CcSEcCtD
Repaglinide—Anaphylactic shock—Irinotecan—colon cancer	0.000306	0.00614	CcSEcCtD
Repaglinide—Chest pain—Fluorouracil—colon cancer	0.000305	0.00614	CcSEcCtD
Repaglinide—Hepatobiliary disease—Capecitabine—colon cancer	0.000303	0.0061	CcSEcCtD
Repaglinide—Thrombocytopenia—Irinotecan—colon cancer	0.000299	0.00602	CcSEcCtD
Repaglinide—Anaphylactic shock—Fluorouracil—colon cancer	0.000293	0.00588	CcSEcCtD
Repaglinide—Oedema—Fluorouracil—colon cancer	0.000293	0.00588	CcSEcCtD
Repaglinide—Rhinitis—Capecitabine—colon cancer	0.000289	0.0058	CcSEcCtD
Repaglinide—Hepatitis—Capecitabine—colon cancer	0.000288	0.00579	CcSEcCtD
Repaglinide—Thrombocytopenia—Fluorouracil—colon cancer	0.000287	0.00576	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000286	0.00575	CcSEcCtD
Repaglinide—Oedema peripheral—Capecitabine—colon cancer	0.000284	0.0057	CcSEcCtD
Repaglinide—Paraesthesia—Vincristine—colon cancer	0.000282	0.00567	CcSEcCtD
Repaglinide—Visual impairment—Capecitabine—colon cancer	0.000278	0.00558	CcSEcCtD
Repaglinide—Paraesthesia—Irinotecan—colon cancer	0.000275	0.00552	CcSEcCtD
Repaglinide—Erythema multiforme—Capecitabine—colon cancer	0.000272	0.00547	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Vincristine—colon cancer	0.000271	0.00545	CcSEcCtD
Repaglinide—Eye disorder—Capecitabine—colon cancer	0.000269	0.00541	CcSEcCtD
Repaglinide—Dyspepsia—Irinotecan—colon cancer	0.000269	0.00541	CcSEcCtD
Repaglinide—Constipation—Vincristine—colon cancer	0.000268	0.0054	CcSEcCtD
Repaglinide—Cardiac disorder—Capecitabine—colon cancer	0.000267	0.00537	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000267	0.00536	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000264	0.0053	CcSEcCtD
Repaglinide—Paraesthesia—Fluorouracil—colon cancer	0.000263	0.00528	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—colon cancer	0.000263	0.00528	CcSEcCtD
Repaglinide—Constipation—Irinotecan—colon cancer	0.000261	0.00525	CcSEcCtD
Repaglinide—Immune system disorder—Capecitabine—colon cancer	0.00026	0.00523	CcSEcCtD
Repaglinide—Dyspepsia—Fluorouracil—colon cancer	0.000258	0.00518	CcSEcCtD
Repaglinide—Arrhythmia—Capecitabine—colon cancer	0.000257	0.00517	CcSEcCtD
Repaglinide—Gastrointestinal pain—Vincristine—colon cancer	0.000257	0.00516	CcSEcCtD
Repaglinide—Alopecia—Capecitabine—colon cancer	0.000255	0.00511	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000253	0.00508	CcSEcCtD
Repaglinide—Erythema—Capecitabine—colon cancer	0.000251	0.00504	CcSEcCtD
Repaglinide—Malnutrition—Capecitabine—colon cancer	0.000251	0.00504	CcSEcCtD
Repaglinide—Gastrointestinal pain—Irinotecan—colon cancer	0.00025	0.00502	CcSEcCtD
Repaglinide—Abdominal pain—Vincristine—colon cancer	0.000248	0.00499	CcSEcCtD
Repaglinide—Back pain—Capecitabine—colon cancer	0.000243	0.00487	CcSEcCtD
Repaglinide—Abdominal pain—Irinotecan—colon cancer	0.000242	0.00486	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000237	0.00476	CcSEcCtD
Repaglinide—CYP3A4—liver—colon cancer	0.000235	0.0104	CbGeAlD
Repaglinide—Urticaria—Fluorouracil—colon cancer	0.000233	0.00468	CcSEcCtD
Repaglinide—Hypersensitivity—Vincristine—colon cancer	0.000231	0.00465	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—colon cancer	0.000226	0.00454	CcSEcCtD
Repaglinide—Hypersensitivity—Irinotecan—colon cancer	0.000225	0.00453	CcSEcCtD
Repaglinide—Leukopenia—Capecitabine—colon cancer	0.000224	0.00451	CcSEcCtD
Repaglinide—Palpitations—Capecitabine—colon cancer	0.000222	0.00445	CcSEcCtD
Repaglinide—Hypertension—Capecitabine—colon cancer	0.000216	0.00435	CcSEcCtD
Repaglinide—Hypersensitivity—Fluorouracil—colon cancer	0.000216	0.00434	CcSEcCtD
Repaglinide—Diarrhoea—Vincristine—colon cancer	0.000215	0.00432	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—colon cancer	0.000214	0.00431	CcSEcCtD
Repaglinide—Arthralgia—Capecitabine—colon cancer	0.000213	0.00429	CcSEcCtD
Repaglinide—Chest pain—Capecitabine—colon cancer	0.000213	0.00429	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000212	0.00426	CcSEcCtD
Repaglinide—Diarrhoea—Irinotecan—colon cancer	0.000209	0.0042	CcSEcCtD
Repaglinide—Pruritus—Fluorouracil—colon cancer	0.000207	0.00416	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—colon cancer	0.000207	0.00415	CcSEcCtD
Repaglinide—Oedema—Capecitabine—colon cancer	0.000205	0.00411	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—colon cancer	0.000203	0.00407	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—colon cancer	0.0002	0.00403	CcSEcCtD
Repaglinide—Diarrhoea—Fluorouracil—colon cancer	0.0002	0.00403	CcSEcCtD
Repaglinide—Thrombocytopenia—Capecitabine—colon cancer	0.0002	0.00403	CcSEcCtD
Repaglinide—Vomiting—Vincristine—colon cancer	0.0002	0.00401	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—colon cancer	0.000199	0.004	CcSEcCtD
Repaglinide—Skin disorder—Capecitabine—colon cancer	0.000199	0.00399	CcSEcCtD
Repaglinide—Rash—Vincristine—colon cancer	0.000198	0.00398	CcSEcCtD
Repaglinide—Dermatitis—Vincristine—colon cancer	0.000198	0.00397	CcSEcCtD
Repaglinide—Headache—Vincristine—colon cancer	0.000197	0.00395	CcSEcCtD
Repaglinide—Vomiting—Irinotecan—colon cancer	0.000194	0.00391	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—colon cancer	0.000194	0.00389	CcSEcCtD
Repaglinide—Rash—Irinotecan—colon cancer	0.000193	0.00387	CcSEcCtD
Repaglinide—Dermatitis—Irinotecan—colon cancer	0.000193	0.00387	CcSEcCtD
Repaglinide—Headache—Irinotecan—colon cancer	0.000192	0.00385	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—colon cancer	0.000189	0.00381	CcSEcCtD
Repaglinide—Erythema—Methotrexate—colon cancer	0.000187	0.00375	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—colon cancer	0.000187	0.00375	CcSEcCtD
Repaglinide—Nausea—Vincristine—colon cancer	0.000186	0.00375	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000186	0.00375	CcSEcCtD
Repaglinide—Vomiting—Fluorouracil—colon cancer	0.000186	0.00374	CcSEcCtD
Repaglinide—Rash—Fluorouracil—colon cancer	0.000185	0.00371	CcSEcCtD
Repaglinide—Dermatitis—Fluorouracil—colon cancer	0.000184	0.00371	CcSEcCtD
Repaglinide—Paraesthesia—Capecitabine—colon cancer	0.000184	0.00369	CcSEcCtD
Repaglinide—Headache—Fluorouracil—colon cancer	0.000183	0.00369	CcSEcCtD
Repaglinide—Nausea—Irinotecan—colon cancer	0.000182	0.00365	CcSEcCtD
Repaglinide—Back pain—Methotrexate—colon cancer	0.000181	0.00363	CcSEcCtD
Repaglinide—Dyspepsia—Capecitabine—colon cancer	0.00018	0.00362	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000177	0.00355	CcSEcCtD
Repaglinide—Constipation—Capecitabine—colon cancer	0.000175	0.00352	CcSEcCtD
Repaglinide—Nausea—Fluorouracil—colon cancer	0.000174	0.0035	CcSEcCtD
Repaglinide—Gastrointestinal pain—Capecitabine—colon cancer	0.000167	0.00336	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—colon cancer	0.000167	0.00336	CcSEcCtD
Repaglinide—Urticaria—Capecitabine—colon cancer	0.000163	0.00327	CcSEcCtD
Repaglinide—Abdominal pain—Capecitabine—colon cancer	0.000162	0.00325	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—colon cancer	0.000159	0.00319	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—colon cancer	0.000159	0.00319	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000158	0.00317	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—colon cancer	0.000152	0.00306	CcSEcCtD
Repaglinide—Hypersensitivity—Capecitabine—colon cancer	0.000151	0.00303	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—colon cancer	0.000149	0.003	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—colon cancer	0.000148	0.00297	CcSEcCtD
Repaglinide—Pruritus—Capecitabine—colon cancer	0.000145	0.00291	CcSEcCtD
Repaglinide—Diarrhoea—Capecitabine—colon cancer	0.00014	0.00281	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000139	0.00279	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—colon cancer	0.000137	0.00275	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—colon cancer	0.000134	0.00269	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000132	0.00264	CcSEcCtD
Repaglinide—Vomiting—Capecitabine—colon cancer	0.00013	0.00261	CcSEcCtD
Repaglinide—Rash—Capecitabine—colon cancer	0.000129	0.00259	CcSEcCtD
Repaglinide—Dermatitis—Capecitabine—colon cancer	0.000129	0.00259	CcSEcCtD
Repaglinide—Headache—Capecitabine—colon cancer	0.000128	0.00258	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—colon cancer	0.000125	0.0025	CcSEcCtD
Repaglinide—Nausea—Capecitabine—colon cancer	0.000122	0.00244	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—colon cancer	0.000121	0.00243	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—colon cancer	0.00012	0.00242	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—colon cancer	0.000112	0.00226	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—colon cancer	0.000108	0.00217	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—colon cancer	0.000104	0.00209	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—colon cancer	9.69e-05	0.00195	CcSEcCtD
Repaglinide—Rash—Methotrexate—colon cancer	9.6e-05	0.00193	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—colon cancer	9.6e-05	0.00193	CcSEcCtD
Repaglinide—Headache—Methotrexate—colon cancer	9.54e-05	0.00192	CcSEcCtD
Repaglinide—Nausea—Methotrexate—colon cancer	9.05e-05	0.00182	CcSEcCtD
